Zevra Therapeutics
Update in progressZVRA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Zevra Therapeutics, Inc. is a commercial-stage company focused on unmet needs in U.S. rare diseases. Using its Ligand Activated Technology, its lead candidate, KP1077, includes KP1077IH and KP1077N in Phase 3 trials for idiopathic hypersomnia and narcolepsy. Celiprolol is in Phase 3 for vascular Ehlers–Danlos syndrome. Also marketed are AZSTARYS for ADHD, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick type C. Partnerships include Commave Therapeutics SA and Acer/Relief Therapeutics. Formerly KemPharm, renamed 2023; founded 2006, Boston.
Company score
- Sentiment
- 0.35
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Neil F. McFarlane
- Founded2006
- Employees61
- Websitewww.zevra.com
Identifiers
- ISINUS4884452065
- FIGIBBG0026ZG1F5
- LEI254900CU6T74V18Y1W18
- CIK0001434647